1492 Capital Management LLC Acquires Shares of 27,424 Lantheus Holdings, Inc. $LNTH

1492 Capital Management LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 27,424 shares of the medical equipment provider’s stock, valued at approximately $2,080,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. M&T Bank Corp purchased a new stake in shares of Lantheus during the fourth quarter valued at approximately $370,950,000. Farallon Capital Management LLC lifted its stake in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after acquiring an additional 1,950,252 shares during the period. Reinhart Partners LLC. boosted its holdings in shares of Lantheus by 15.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after acquiring an additional 214,820 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after acquiring an additional 44,374 shares during the period. Finally, Norges Bank bought a new stake in shares of Lantheus in the fourth quarter worth approximately $76,197,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 0.7%

NASDAQ:LNTH opened at $109.80 on Friday. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.46. The business has a fifty day moving average price of $95.88 and a 200-day moving average price of $79.87. The firm has a market capitalization of $7.15 billion, a price-to-earnings ratio of 26.46 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.49 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research analyst reports. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Citizens Jmp lifted their target price on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Mizuho boosted their target price on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, Truist Financial restated a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.